Neok Bio
PrivateLast Round
Series A
Extension
Mar 30, 2026
Est. Valuation
$116.5M
Total Funding Raised
$100M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Neok Bio is a biotechnology company that develops novel bispecific antibody drug conjugates (ADCs) for the treatment of solid tumors.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Neok Bio Comparables
Compare Neok Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Sidewinder | 87% | |
| Genmab A/S | 83% | |
| Promatix Biosciences | 81% |
Neok Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Mar 30, 2026 | ||||
| Series A | Nov 4, 2025 |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 6, 2026
Monthly visitors grew 904% MoM, reaching 4.1K.
- Mar 30, 2026
$25M round led by ABL Bio, Inc.
Neok Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access